Chromogranin a staining as a prognostic variable in newly diagnosed Gleason score 7-10 prostate cancer treated with definitive radiotherapy

Prostate

Volumn 74, Issue 5, 2014, Pages 520-527

  Krauss, Daniel J ^a   Amin, Mitual ^a   Stone, Brandon ^a   Ye, Hong ^a   Hayek, Sylvia ^a   Cotant, Matthew ^a   Hafron, Jason ^a   Brabbins, Donald S ^a  

^a OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

Author keywords

chromogranin A; neuroendocrine differentiation; prostate cancer

Indexed keywords

CHROMOGRANIN A; NEUROENDOCRINE DIFFERENTIATION; PROSTATE CANCER;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CHROMOGRANIN A; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84894252958     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22771     Document Type: Article

References (31)

1. Krauss DJ, Hayek S, Amin M, Ye H, Kestin LL, Zadora S, Vicini FA, Cotant M, Brabbins DS, Ghilezan MI, Gustafson GS, Martinez AA,. Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 2011; 81: e119-e125.
2. Palmgren JS, Karavadia SS, Wakefield MR,. Unusual and underappreciated: Small cell carcinoma of the prostate. Semin Oncol 2007; 34: 22-29. (Pubitemid 46161758)
3. Vashchenko N, Abrahamsson P,. Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities. Eur Urol 2005; 47: 147-155. (Pubitemid 40126970)
4. Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, van Krimpen H, Schroder FH, van der Kwast TH,. Do neuroendocrine cells in human prostate cancer express androgen receptor ? Histochemistry 1993; 100: 393-398. (Pubitemid 23355975)
5. Bonkhoff H,. Neuroendocrine cells in benign and malignant prostate tissue: Morphogenesis, proliferation, and androgen receptor status. Prostate Suppl 1998; 8: 18-22. (Pubitemid 28347991)
6. Fixemer T, Remberger K, Bonkhoff H,. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate 2002; 53: 118-123.
7. Vargas C, Yan D, Kestin LL, Krauss D, Lockman DM, Brabbins DS, Martinez AA,. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: Use of dose-volume constraints to achieve rectal isotoxicity. Int J Radiat Oncol Biol Phys 2005; 63: 141-149. (Pubitemid 41583552)
8. Brabbins D, Martinez A, Yan D, Lockman D, Wallace M, Gustafson G, Chen P, Vicini F, Wong J,. A dose escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: Analysis of chronic toxicity. Int J Radiat Oncol Biol Phys 2005; 61: 400-408. (Pubitemid 40164433)
9. Martinez A, Gonzalez J, Ye H, Ghilezan M, Shetty S, Kernen K, Gustafson G, Krauss D, Vicini F, Kestin L,. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011; 79: 363-370.
10. Martinez A, Gustafson G, Gonzalez J, Armour E, Mitchell C, Edmundson G, Spencer W, Stromberg J, Huang R, Vicini F,. Dose escalation using conformal high dose rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 316-327. (Pubitemid 34522097)
11. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU,. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011; 365: 107-118.
12. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Torecilla JL, Pfeffer JR, Cutajar CL, Zurlo A, Pierart M,. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 2002; 360: 103-108. (Pubitemid 34786197)
13. Pilepich MV, Winter K, Lawton CA, Krisch RE, Walkov HB, Movsas B, Hug E, Asbell SO, Grignon D,. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-1290. (Pubitemid 40470408)
14. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW,. 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004; 292: 821-827. (Pubitemid 39079668)
15. Noordzij MA, van der Kwast TH, Steenbrugge GJ, Hop WJ, Schroder FH,. The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 1995; 62: 252-258.
16. Ahlegren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA,. Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. Urology 2000; 56: 1011-1015.
17. Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L,. Neuroendocrine expression in node positive prostate cancer: Correlation with systemic progression and patient survival. J Urol 2002; 168: 1204-1211.
18. Veltri RW, Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, Partin AW,. Long-term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape, and molecular biomarkers of pathogenesis. Prostate 2008; 68: 1806-1815.
19. Revelos K, Petraki C, Scorilas A, Alevizopoulos N, Kanellis G, Halapas A, Koutsilieris M,. Correlation of androgen receptor status, neuroendocrine differentiation, and angiogenesis with time to biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res 2007; 27 (5B): 3651-3660. (Pubitemid 47607515)
20. Berruti A, Bollito E, Cracco CM, Volante M, Ciccone G, Porpiglia F, Papotti M, Scarpa RM, Dogliotti L,. The prognostic role of immunohistochemical chromogranin A expression in prostate cancer patients is significantly modified by androgen deprivation therapy. Prostate 2010; 70: 718-726.
21. Sciarra A, Gentile V, Autran Gomez AM, Salciccia S, Gentilucci A, Monti S, Toscano V, Di Silverio F,. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy. Endocr Relat Cancer 2007; 625-632.
22. Theodorescu D, Broder SR, Boyd JC, Mills SE,., Frierson HF Jr., Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 1997; 80: 2109-2119. (Pubitemid 27506024)
23. May M, Siegsmund M, Hammermann F, Loy V, Gunia S,. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy. Scand J Urol Nephrol 2007; 41: 375-381. (Pubitemid 350034696)
24. Weinstein MH, Partin AW, Veltri RW, Epstein JI,. Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996; 27: 683-687. (Pubitemid 26240320)
25. Klocker H, Culig Z, Hobisch A, Cato AC, Bartsch G,. Androgen receptor alterations in prostatic carcinoma. Prostate 1994; 25: 266-273. (Pubitemid 24364131)
26. Veldscholte J, Ris-Staples C, Kuiper GJ, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E,. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Comm 1990; 173: 534-540.
27. Abrahamsson PA,. Neuroendocrine cells in tumor growth of the prostate. Endocr Rel Cancer 1999; 6: 503-519.
28. Debes JD, Tindallo DJ,. The role of androgens and the androgen receptor in prostate cancer. Cancer Lett 2002; 187: 1-7. (Pubitemid 35279326)
29. Ueda T, Bruchovsky N, Sadar MD,. Activation of androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002; 277: 7076-7085. (Pubitemid 34959964)
30. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H,. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54: 5474-5478.
31. Beltran H, Rickman D, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA,. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discovery 2011; 1 (6): 487-495.